CYP2D6 and breast cancer: In conclusion, we could not find a negative effect of SSRI use during tamoxifen treatment with respect to risk of breast cancer death even in subgroups of patients that the biological rationale behind the hypothesis was supposed to be stronger (use of strong CYP2D6-inhibitors or use of SSRIs for a long period concomitant with tamoxifen).